Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
“This Orphan Drug Designation is an important component in our strategy to evaluate potential expanded uses of ZX008 in other rare and severe epilepsy conditions,” said
Orphan Drug Designation is granted by the EC to drugs that are intended for the treatment of life-threatening or chronically debilitating, rare diseases where no satisfactory treatment of the condition concerned is authorized. If such a treatment exists, then the medicine must be of significant benefit to those affected by the condition. Rare diseases are those defined as having a prevalence of not more than five per 10,000 population in
For more information, visit www.zogenix.com.
Forward Looking Statements
Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 | Andrew@lifesciadvisors.com